lifestyle.thedailyhaze.com

Author: Nanoscope Therapeutics

Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness

April 1, 2026
Nanoscope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO-010, Expands Global Regulatory Leadership in Vision Restoration

March 30, 2026
Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease

March 23, 2026
Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting

February 24, 2026
Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases – A First for a Retinal Gene Therapy

January 20, 2026
Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration

January 7, 2026
Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026